A method for detecting biomarkers with shortened test time and maximized precision. A sample from the body fluid is made to flow over a sensor surface coated with a capture antibody to allow binding of a biomarker in the sample to the capture body. An optical method detects and counts the individual binding events along the sensor surface with single molecule resolution, and difference in the binding events along the sensor surface is detected in real time and analyzed to determine the biomarker concentration.

A lateral flow assay (“LFA”) strip for receiving a test sample from a domain. The LFA strip includes a test line on the LFA strip that indicates a positive result in the presence of a chemical-of-interest being tested for in the domain and a negative result in the absence of the chemical-of-interest being tested for in the domain. The strip also includes a verification line on the LFA strip that indicates a positive result when a target marker present in the domain is on the LFA strip.

The invention provides device and method for detecting infection in a body fluid, in particular in wound exudates and urine, based on protease activity. The device is founded on a detector consisting of one layer, which is an absorbent layer impregnated with a solution formed by dissolving a pH sensitive dye, such as bromothymol blue, in a gelatin solution. The method uses the device in form of a test strip for quick detection of an infection by observing a change in the color of the detector.

A handheld Surface-Enhanced Raman Spectroscopy (SERS) device for detecting phenylalanine (Phe) in a sample collected from a subject, the device comprising a laser generator configured to produce a laser beam; a nanoporous anodic aluminum oxide (NAAO) substrate configured to receive the sample collected from the subject; and a light sensor configured to receive a light.

A method for quantification of the concentration of one or more cannabinoid compounds in a liquid sample is provided. The method involves contacting the liquid sample with at least one cannabinoid-sensitive visualization reagent, allowing the at least one cannabinoid-sensitive visualization reagent to develop for a defined amount of time; and comparing the resulting color change of the at least one cannabinoid-sensitive visualization reagent to a calibrated quantification reference chart.

A test strip includes a substantially transparent substrate and one or more colorimetric test spots on the transparent substrate. Each colorimetric test spot has one or more sensing chemicals chemically attached onto a porous support material. The porous support material has at least one exposed surface configured to absorb a body fluid. The one or more sensing chemicals are configured to change a color in response to a presence of a target drug in the body fluid.

A test strip assembly 101 for dipping in a bodily fluid sample to analyse a presence or absence of one or more analytes is provided. The test strip assembly 101 includes a basal layer (1), a first adhesive layer (2) that is entirely present over the basal layer (1) a porous membrane (3) that is present over the first adhesive layer (2) and the bodily fluid flows in a lateral direction in the porous membrane (3); a second adhesive layer (4); and a number of detection labels (5) placed on the porous membrane through the adhesive layer (4) and receives bodily fluids flowing in the lateral direction in the porous membrane such that the bodily fluids then flow in a vertical direction in the detection labels (5). A device including the test strip assembly (101) is provided.

A method for detecting biomarkers with shortened test time and enhanced precision is provided. A sample from the body fluid is made to flow over a sensor surface coated with a capture antibody to allow binding of a biomarker in the sample to the capture body. An optical method detects and counts the individual binding events along the sensor surface with single molecule resolution, and difference in the binding events along the sensor surface is detected in real-time and analyzed to determine the biomarker concentration.

Provided are a diagnostic system and methods for detecting the presence or absence of one or more targets that represent virus infection, inflammatory diseases and/or respiratory disorders by optically and noninvasively observing changing in color of the diagnostic system upon binding of the antigen of interest. Exemplary diagnostic systems and methods include detection of SARS-CoV-2 virus S protein or receptor of advanced glycation end products (RAGE) for diagnosis of COVID-19 infection or inflammatory/respiratory diseases.

Certain aspects of the present disclosure generally relate to systems and methods for determining viruses such as coronaviruses. For instance, some aspects are directed to systems and methods for determining viruses using a partitioning system. Within the partitioning system, free RNA or other nucleic acids may preferentially partition into one phase, while intact viruses may be present in the other phase or in both phases. Accordingly, in some cases, free RNA or other nucleic acids may be preferentially removed, e.g., as compared to intact RNA or other nucleic acids present within a virus. In some cases, the phase containing intact viruses can be determined to determine the infectiousness, e.g., of a sample arising from a subject. This may be useful, for example, for distinguishing subjects who are capable of spreading an infection from those who are not infectious.